Anagrelide
- TRADE NAMES: Agrylin (Shire); Xagrid (Shire)
- INDICATIONS: Essential thrombocytopenia; to reduce elevated platelet count and the risk of thrombosis
- CLASS: Phospholipase A2 inhibitor
- HALF-LIFE: 1.3 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Aminophylline, Aspirin, Cilostazol, Enoximone, Fluvoxamine, Fondaparinux, Inamrinone, Milrinone, Olprinone, Sucralfate
PREGNANCY CATEGORY: C
Contraindicated in patients with severe hepatic impairment.
Please login to see the rest of this drug profile
SKIN.
HAIR.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OTIC.
RESPIRATORY.
OTHER.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric